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Abstract
Background: Retrospective analysis of Center effect of the multi-center trial conducted to compare Immucothel (KLH
Immunotherapy drug product) with Mytomycin-C (MM) concluded that efficacy evaluation of the drug product may
be impacted by physician’s subjective performance of Transurethral resection of bladder tumor (TURBT).
Methods: A randomized trial was performed in 18 hospitals (clinical centers) and a total of 553 recruited, 283 patients
under KLH arm and 270 patients under MM. An initial statistical analysis of efficacy comparisons between KLH and MM
based on log-rank test performed for each center (hospital) showed 6 hospitals out of 18 hospitals a p-value of <0.05
and remaining 12 hospitals showed a p-values of >0.05. No association was observed between number of patients
analysed and the associated p-values across hospitals. Final statistical analyses were carried out under each drug
product using Kaplan-Meier survival analysis along with log-rank test after combining all eligible patients data for 6
hospital group and 12 hospital group.
Results: Median recurrence free survival (RFS) times (in weeks) showed statistical significance (p-value = 0.03) between
two groups of hospitals under KLH arm, while similar median values showed no statistical significance (p-value = 0.05).
Conclusion: Center effect with respect to median RFS values under KLH was more pronounced than under MM. Under
the presence of such center effect, for reasons other than product related effects, concluding superiority of one drug
product over another may create confounding bias conclusions in multi-center clinical trials. In the above cited clinical
trial study, physician’s prior experience on TURBT might have contributed to center effect in examining efficacies of KLH
and MM. Similar observation was also noted in the literature on studies dealing with TURBT and in other clinical studies.
Trial registration: Data set used in this study is based on previously documented clinical trial in the literature: See
(Lammers et al., J Clin Oncol 30:2273–9, 2012) and Acknowledgments.
Background
Intravesical bacillus Calmette-Guérin (BCG) instillation re-
mains the standard treatment among intravesical anticancer
therapies after transurethral resection (TURBT) for bladder
cancer, to suppress disease recurrence and progression [1].
Since the toxicity of BCG is a limitation in some patients,
other alternative intravesical chemotherapeutic agents have
been developed. One such cytostatic agent is mitomycin C
(MM). IMMUCOTHEL® (Keyhole Limpet Hemocyanin
(KLH) Immunotherapy drug product, biosyn, Fellbach,
Germany) is an approved drug product for the prevention
of bladder carcinoma recurrence after TURBT and after
failure of other established therapies, like BCG and MM.
A randomized phase III trial based on 553 patients
(283 patients under KLH and 270 patients under MM),
with intermediate- and high-risk non-muscle-invasive
bladder cancer (NMIBC) without carcinoma in situ has
been performed and the study details are published [2].
The multicenter trial spanned over 18 clinical centers
(hospitals). In the phase III trial study patients were
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randomized into the KLH arm or the MM arm after
TURBT. In the KLH arm, patients received 1 mg KLH
preimmunization followed by instillations with 20 mg
KLH once per week for 6 weeks and once per month for
10 months for a total targeted 16 instillations as part of
the KLH treatment. In the MM arm, patients received
40 mg MM once per week for 4 weeks and followed by
five monthly instillations, and then at 9 and 12 months
for a total targeted 11 instillations. The efficacy compari-
son between KLH and MM was based on median
recurrence-free survival (RFS) and recurrence rate [2].
The present work focus is on exploratory evaluation of
a treatment-by-centre interaction effect through statis-
tical significance tests for treatment effects within each
centre based on ICH Guidance [3].
Material and Methods
Patient demographic and clinical characteristics of the
multicenter phase III clinical trial have already been
published by Lammers et al. (Table 1) [2]. Initial
analysis of the 18 individual hospitals’ data was per-
formed using the by Kaplan-Meier method and hazard
ratio (HR) using the Cox PH model. The statistical
analysis is summarized in Table 1.
The overall HR (18 centers) is 2.26 as reported by
Lammers et al. [2] and confirmed in our analysis. The
hospital grouping based on HR and p values shows a
fairly good overall correlation. All the hospitals (5 out of
5, 100%) with p < 0.05 have a HR value greater than 2.26
and majority of hospital (9 out of 11, 81%) with p > 0.05
have a HR value less than 2.26. The HR values for two
hospitals, 17 and 18, are not reported as there was no
recurrence in MM treatment arm (Table 1). In view of
these observations subsequent analysis was performed
using hospital grouping based on p values.
In Table 1, the p value for six hospitals (shaded in
gray) was statistically significant; p value < 0.05. Those
six centers were designated as group 1. The remaining
12 hospitals had a p value > 0.05 and were pooled in
group 2. The patient demographic and clinical charac-
teristics of all patients for group 1 and group 2 are
summarized in Table 2.
Group 1 represents six hospitals, which show a statisti-
cally significant difference (p value < 0.05) between the two
treatment groups. The data in group 1 consists of 95 pa-
tients in the KLH treatment arm and 90 patients for MM.
Group 2 represents the remaining 12 hospitals, which dis-
played no statistically significant difference (p value > 0.05).
Group 2 includes 172 patients for KLH and 166 for MM.
The median RFS and recurrence rates for KLH and
MM were derived by Kaplan-Meier survival analysis.
Comparison of median RFS using the log-rank test was
performed for the same drug product (KLH or MM)
between group 1 and group 2.
Table 1 Summary of recurrences, p value (log-rank) and hazard ratio (HR) values (Cox PH) for 18 trial centers
Hospitals with p < 0.05 highlighted in gray
*HR value larger than 2.26 (over all HR value based on all 18 hospitals)
**HR value not available since no recurrences in the mitomycin C group
KLH Keyhole Limpet Hemocyanin, MM mitomycin C, TURBT transurethral resection of bladder tumor
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Results and Discussion
Significant differences between trial centers
The analysis of the 18 individual trial centers showed signifi-
cant differences for six hospitals (p < 0.05) for both treat-
ment arms. Therefore, those six centers were designated as
group 1 and the remaining 12 hospitals were pooled in
group 2 (Table 1). In total, 95 patients (35.6%) received KLH
and 90 (35.2%) patients were treated with MM in group 1.
In group 2, 172 patients (64.4%) were treated with KLH and
166 (64.8%) received MM (Table 3). Patient demographic
and clinical characteristics are shown in Table 2. The data
suggests that the distribution of patients for KLH and MM
arms is similar between group 1 and group 2.
Recurrence rate and median RFS were significantly
different within treatment arms
The recurrence rate and median RFS for KLH and MM
in group 1 and group 2 are summarized in Table 4. For
the KLH treatment arm, 74% (70 out of 95 patients)
developed a recurrence in group 1 as compared to 54%
(93 out of 172 patients) in group 2 (p value = 0.03, chi-
square test). For the MM treatment arm, 26% (23 out
of 90 patients) developed a recurrence in group 1 as
compared to 39% (64 out of 166 patients) in group 2
(p value = 0.05, chi-squared test).
The median RFS for KLH in group 1 is 84 weeks com-
pared to 139 weeks for median RFS for KLH in group 2.
The median RFS for group 1 is significantly lower than
group 2 (p = 0.004, log-rank test). Similarly, the median
RFS for group 1 is not attained for MM compared to a
median RFS value of 297 for group 2 (approaching
significance p = 0.05, log-rank test).
Similar results for recurrence rate and medium RFS
were obtained when the hospital grouping was per-
formed based on HR values (low <2.26 and high >2.26)
(details not reported; see Additional files 1 and 2).
Table 2 Patient demographic and clinical characteristics of all patients within the two hospital groups
Characteristic KLH MM Total
Group 2 Group 1 Group 2 Group 1 KLH MM
N % N % N % N %
Number of patients 172 64.4 95 35.6 166 64.8 90 35.2 267 256
Sex
Male 141 82 77 81.1 133 80.1 77 85.6 218 210
Female 31 18 18 18.9 33 19.9 13 14.4 49 46
Mean age in years 37.6 36.8 35.6 47.9
Tumor status
Primary 100 58.1 44 46.3 102 61.4 44 48.9 144 146
Recurrent 72 41.9 51 53.7 64 38.6 46 51.1 123 110
Previous treatment in patients with recurrent tumors at baseline
Current single post-TURBT intravesical chemotherapy 2 3 1 1 5 2
Previous single post-TURBT intravesical chemotherapy 8 2 2 1 10 3
Local adjuvant intravesical therapy 20 11 12 15 31 27
Other therapy 3 3 3
No therapy other than TURBT 39 35 49 29 74 78
Tumor stage
pTa 132 76.7 84 88.4 113 68.1 71 78.9 216 184
pT1 40 23.3 11 11.6 53 31.9 19 21.1 51 72
Tumor grade
1 54 31.4 34 35.8 47 28.3 32 35.6 88 79
2 95 55.2 53 55.8 87 52.4 47 52.2 148 134
3 23 13.4 8 8.4 32 19.3 11 12.2 31 43
Number of tumors
Single 60 34.9 29 34.9 57 34.3 26 28.9 89 83
Multiple 112 65.1 66 69.5 108 65.1 64 71.1 178 172
Unknown 1 1
KLH Keyhole Limpet Hemocyanin, MM mitomycin C, TURBT transurethral resection of bladder tumor
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These results imply that the same drug product has
better efficacy in one group compared to the other.
Logically, this would be an unlikely scenario and sug-
gests that other center-related effects may be involved in
this study.
Significant influence of prior TURBT in multi-center trial
The study design called for TURBT prior to randomizing
the patients into each treatment arm. Existing medical lit-
erature data suggests that outcome of TURBT with regard
to recurrence is significantly influenced by the operative
experience of the surgeon [4–10]. The results of this ana-
lysis provide additional evidence to the referenced existing
medical literature data. The observed differences between
group 1 and group 2 hospitals were possibly due to differ-
ences in the operative experience of the surgeons.
What are the possible approaches that can be taken in
the design of clinical trials to overcome this TURBT-
related variability in evaluating new drug product effica-
cies? One approach could be recruiting patients who
have undergone at least one TURBT procedure. In this
regard, we have performed a subgroup analysis of
patients receiving 16 KLH instillations or 11 MM instil-
lations and who had prior recurrent tumors (n = 156;
KLH = 67 and MM= 89). The results showed that the
percentage of recurrences for KLH-treated patients was
54% while the percentage of recurrence for MM treated
patients was 38%. Statistical evaluation of product effi-
cacy (chi-squared test) indicated that the two groups are
not significantly different (p = 0.107).
Further supporting data has been reported by
Lammers et al. [2]. Subgroup analysis performed for
patients with recurrent disease and a history of intra-
vesical treatments, the number of patients with recur-
rences and time to recurrence was not statistically
different for the KLH and MM treatment groups.
Different efficacy profile for KLH and mitomycin C
exacerbate influence of TURBT on therapy outcome
KLH is a nonspecific immunotherapeutic agent and
unlike chemotherapeutics, such as mitomycin C, the
immunotherapeutic effect to take hold requires some
lead time to produce a positive outcome in patients
and, as such, the treatment course includes 16 instilla-
tions over a 12-month time period. KLH (IMMU-
COTHEL®) is approved as a second-line treatment.
Therefore, subgroup analysis was performed for pa-
tients with recurrent disease and a complete treatment
course who had received an additional treatment after
TURBT for prior tumor. The number of patients with
recurrences (45% versus 52%) and time to recurrence
(235 versus 98 weeks) was not statistically different for
the KLH and MM treatment groups (p ~ 1.0, respect-
ively, p = 0.549) (Table 5).
In general, it appears that the recurrence rate be-
tween institutions or multiple clinical studies for
bladder cancer patients treated with any of the cur-
rently used drug products (BCG and MM included)
has a large variability [2, 4, 9].
Table 4 Recurrence rate and median recurrence-free survival (RFS) for Keyhole Limpet Hemocyanin (KLH) and mitomycin C (MM) for










Lower bound Upper bound
KLH Group 1 74 84 64 103
Group 2 54 139 100 178
Mitomycin C Group 1 26 N/Ab N/Ab N/Ab
Group 2 39 297 152 442
aGroup 1 = 6 hospitals, Group 2 = 12 hospitals
bNot attainable
Table 3 Frequency of subjects and number of recurrences in the two hospital groups
Treatment received Hospital groupa Total N N of events (# of recurrences) Recurrences in [%]
KLH Group 1 95 70 74
Group 2 172 93 54
Overall 267 163 61
Mitomycin C Group 1 90 23 26
Group 2 166 64 39
Overall 256 87 34
aGroup 1 = 6 hospitals, Group 2 = 12 hospitals
KLH Keyhole Limpet Hemocyanin
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Conclusion
The results of the prospective, randomized, multicenter,
phase III clinical trial, “Intracutaneous and Intravesical
Immunotherapy with Keyhole Limpet Hemocyanin
Compared with Intravesical Mitomycin in Patients with
Non-Muscle-Invasive Bladder Cancer,” have been pub-
lished [2]. The authors concluded that KLH has a differ-
ent safety profile and is inferior to MM in preventing
non-muscle-invasive bladder cancer.
This retrospective analysis of the same clinical data
focused on evaluating center effects on product efficacy.
From the statistical analysis of the individual centers, we
identified two sets of hospital groups based on the p
values (p < 0.05 and p > 0.05). The results indicate that
the majority of the hospitals showed no statistical differ-
ence between KLH and MM with respect to median
RFS. This suggests the presence of center effects in this
clinical trial as evidenced by statistical comparison of the
same drug product (KLH or MM) between the two hos-
pital groups. The conclusion of this data would be that
the same drug product is superior to itself between the
two centers. As this is an illogical conclusion; among
other possible determining factors, the TURBT proced-
ure is suspected to be the main contributing factor. The
patient data summary in Tables 1 and 2 suggests that
there is no selection bias arising due to clinical and
demographic patient characteristics. Such selection bias
would normally be a prime determining factor but is not
present in this well-designed clinical trial. Similar suspi-
cions have been raised by other reports as it relates to
variable observed recurrence rates between institutions.
This report specifically expands on that concept to show
that it has an effect on the efficacy determination of
drug products.
This suggests that when performing new drug efficacy
evaluation studies involving surgery as a prerequisite
step, as is the case with bladder cancer, the operative
experience of the surgeon [10, 11] is an additional
important factor for consideration in designing future
clinical studies.
In view of such differences in the efficacy of the same
product used on patients in two groups of hospitals,
proper care and procedures need to be taken in generaliz-
ing product efficacies. As suggested by Richsterstetter et
al. [8] and Brausi et al. [9], suitable statistical procedures
need to be utilized to account for interaction effect be-
tween product efficacy and multicenter effects before
generalizing results of the clinical study. This additional
confounding effect has to be taken into consideration
when designing clinical trials with new drug products
involving surgery as a prerequisite treatment step.
Once a product is approved, surgeons optimize surgi-
cal technique for a given drug product to provide
improved clinical outcomes for their patients. Such
modifications may be done unintentionally. As a result,
when surgeons perform clinical studies using new prod-
uct candidates, there may be an inherent bias in their
surgical techniques toward their preferred choice of drug
product.
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Table 5 Recurrence rate and median recurrence-free survival (RFS)
for Keyhole Limpet Hemocyanin (KLH) and mitomycin C (MM) in
patients with recurrence and complete treatment course who
received additional treatment after transurethral resection of






Lower bound Upper bound
KLH 48 235 35 435
Mitomycin C 52 98 75 121
Overall 50 210 69 351
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